Biotechnology: Pharmaceutical Preparations

Quarterly ResultAug 13, 2026, 07:32 AM

Ascendis Pharma Q2 Product Revenue €315M, +105% Y/Y

AI Summary

Ascendis Pharma reported strong second-quarter 2026 financial results, with product revenue surging 105% year-over-year to €315 million, driven by robust demand for YORVIPATH®, SKYTROFA®, and YUVIWEL®. The company achieved an operating profit of €220 million and a net profit of €207 million. Key business updates include the settlement of all convertible notes and inclusion in multiple Russell U.S. Indexes.

Key Highlights

Q2 2026 product revenue increased 105% Y/Y to €315 million.
YORVIPATH® revenue was €252 million, SKYTROFA® €55 million, YUVIWEL® €8 million.
Total revenue for Q2 2026 reached €339 million.
Operating profit for Q2 2026 was €220 million.
Net profit for Q2 2026 was €207 million (€2.83 diluted EPS).
Cash and cash equivalents totaled €812 million as of June 30, 2026.
Sold Rare Pediatric Disease Priority Review Voucher for €158 million cash.
Settled all $575 million convertible notes and added to Russell U.S. Indexes.

View SEC Filing

ASND

Biotechnology: Pharmaceutical Preparations

Ascendis Pharma A/S

Price Impact